Negozia BeyondSpring Inc. - BYSI CFD

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company''s lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and developing Plinabulin, which is in Phase III clinical trial for the treatment of later-stage non-small cell lung cancer (NSCLC). It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.